NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced that its independent directors approved an equity award under the company's 2021 Inducement Plan, effective June 24, 2026. The award was granted as a material inducement to an individual entering into employment with NeuroOne, in accordance with Nasdaq Listing Rule 5635(c)(4), which mandates public announcement of such inducement grants not made under a stockholder-approved plan.
The new hire, who was not a previous employee or director of NeuroOne, received an option to purchase 10,000 shares of the company's common stock at an exercise price of $3.27 per share, the closing price on the grant date. The option has a ten-year term and vests over four years, with 25% vesting on June 24, 2027, and the remainder vesting in 12 equal quarterly installments thereafter, contingent upon continued employment. The award is subject to acceleration or forfeiture under certain conditions as outlined in the option agreement.
This inducement grant highlights NeuroOne's focus on attracting talent to support its mission of transforming surgical diagnosis and treatment of neurological disorders. The company markets a minimally invasive, high-definition electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These solutions aim to reduce hospitalizations, lower costs, and improve patient outcomes by offering both diagnostic and therapeutic functions.
NeuroOne is also engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs. The company's stock is listed on Nasdaq under the ticker NMTC. For more information, visit nmtc1.com.
The disclosure of this inducement grant provides transparency to investors and the market, reflecting the company's compliance with Nasdaq listing standards and its strategic use of equity incentives to secure key personnel. As NeuroOne continues to advance its pipeline and commercialize its technologies, such grants play a critical role in building a team capable of driving innovation and growth in the competitive medical technology sector.
